BioNTech founders pursue AI mRNA research
Ugur Sahin and Ozlem Tureci, the founders of BioNTech and pioneers behind the first Western-approved COVID-19 vaccine, are stepping down to explore a new venture. Their departure signifies a notable change in the biotech industry.
Sahin and Tureci are leaving their CEO positions to concentrate on creating AI-driven mRNA therapies, a field that could transform medical treatments. This strategic shift underscores the increasing convergence of artificial intelligence and biotechnology. Their new venture aims to build upon their extensive experience in mRNA technology, potentially leading to groundbreaking advancements in personalized medicine and other therapeutic areas.
Summarized from the sources above. Read the originals for the full story.
Highlights
Founders depart BioNTech
Ugur Sahin and Özlem Türeci are stepping down from BioNTech to start a new venture.
New AI mRNA research
The founders will focus on developing AI-powered mRNA therapies.
Revolutionizing medical treatments
Their new venture aims to potentially revolutionize medical treatments.
Significant shift in biotech
Their departure marks a significant shift in the biotech landscape.
AI and biotechnology intersection
The move highlights the growing intersection of AI and biotechnology.